Literature DB >> 19014370

Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways.

Gregory P McLennan1, Alexi Kiss, Mayumi Miyatake, Mariana M Belcheva, Kari T Chambers, John J Pozek, Yasmin Mohabbat, Robert A Moyer, Laura M Bohn, Carmine J Coscia.   

Abstract

GTP binding regulatory protein (G protein)-coupled receptors can activate MAPK pathways via G protein-dependent and -independent mechanisms. However, the physiological outcomes correlated with the cellular signaling events are not as well characterized. In this study, we examine the involvement of G protein and beta-arrestin 2 pathways in kappa opioid receptor-induced, extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated proliferation of both immortalized and primary astrocyte cultures. As different agonists induce different cellular signaling pathways, we tested the prototypic kappa agonist, U69593 as well as the structurally distinct, non-nitrogenous agonist, C(2)-methoxymethyl salvinorin B (MOM-Sal-B). In immortalized astrocytes, U69593, activated ERK1/2 by a rapid (min) initial stimulation that was sustained over 2 h and increased proliferation. Sequestration of activated Gbetagamma subunits attenuated U69593 stimulation of ERK1/2 and suppressed proliferation in these cells. Furthermore, small interfering RNA silencing of beta-arrestin 2 diminished sustained ERK activation induced by U69593. In contrast, MOM-Sal-B induced only the early phase of ERK1/2 phosphorylation and did not affect proliferation of immortalized astrocytes. In primary astrocytes, U69593 produced the same effects as seen in immortalized astrocytes. MOM-Sal-B elicited sustained ERK1/2 activation which was correlated with increased primary astrocyte proliferation. Proliferative actions of both agonists were abolished by either inhibition of ERK1/2, Gbetagamma subunits or beta-arrestin 2, suggesting that both G protein-dependent and -independent ERK pathways are required for this outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19014370      PMCID: PMC2606093          DOI: 10.1111/j.1471-4159.2008.05745.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  65 in total

Review 1.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

2.  Glia-derived D-serine controls NMDA receptor activity and synaptic memory.

Authors:  Aude Panatier; Dionysia T Theodosis; Jean-Pierre Mothet; Bastien Touquet; Loredano Pollegioni; Dominique A Poulain; Stéphane H R Oliet
Journal:  Cell       Date:  2006-05-19       Impact factor: 41.582

3.  Astrocytes put down the broom and pick up the baton.

Authors:  Jeffrey S Diamond
Journal:  Cell       Date:  2006-05-19       Impact factor: 41.582

4.  Direct astrocytic contacts regulate local maturation of dendritic spines.

Authors:  Hideko Nishida; Shigeo Okabe
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

5.  Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes.

Authors:  Michael R Bruchas; Tara A Macey; Janet D Lowe; Charles Chavkin
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

Review 6.  New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors.

Authors:  Robert J Lefkowitz; Keshava Rajagopal; Erin J Whalen
Journal:  Mol Cell       Date:  2006-12-08       Impact factor: 17.970

7.  Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.

Authors:  Timothy A Vortherms; Philip D Mosier; Richard B Westkaemper; Bryan L Roth
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

8.  An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

Authors:  C E Groer; K Tidgewell; R A Moyer; W W Harding; R B Rothman; T E Prisinzano; L M Bohn
Journal:  Mol Pharmacol       Date:  2006-11-07       Impact factor: 4.436

9.  Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.

Authors:  Jacob M Hooker; Youwen Xu; Wynne Schiffer; Colleen Shea; Pauline Carter; Joanna S Fowler
Journal:  Neuroimage       Date:  2008-03-15       Impact factor: 6.556

10.  Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase.

Authors:  Mei Xu; Michael R Bruchas; Danielle L Ippolito; Louis Gendron; Charles Chavkin
Journal:  J Neurosci       Date:  2007-03-07       Impact factor: 6.167

View more
  43 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  Enhancing Remyelination through a Novel Opioid-Receptor Pathway.

Authors:  Jeremy C Borniger; Zoe C Hesp
Journal:  J Neurosci       Date:  2016-11-23       Impact factor: 6.167

4.  Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Authors:  Miriam Aceves; Eric A Bancroft; Alejandro R Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-11-04       Impact factor: 5.269

5.  Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.

Authors:  Raehannah J Jamshidi; Blaine A Jacobs; Laura C Sullivan; Teresa A Chavera; Rachel M Saylor; Thomas E Prisinzano; William P Clarke; Kelly A Berg
Journal:  J Pharmacol Exp Ther       Date:  2015-08-21       Impact factor: 4.030

Review 6.  Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.

Authors:  I Charfi; N Audet; H Bagheri Tudashki; G Pineyro
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 7.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

Review 8.  Opioid and hypocretin neuromodulation of ventral tegmental area neuronal subpopulations.

Authors:  Taylor S Thomas; Corey Baimel; Stephanie L Borgland
Journal:  Br J Pharmacol       Date:  2017-09-26       Impact factor: 8.739

Review 9.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 10.  Dynorphin, stress, and depression.

Authors:  Allison T Knoll; William A Carlezon
Journal:  Brain Res       Date:  2009-09-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.